ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

April 25, 2014

Robert Day Advocates NCI Payment for Investigator Salaries

May 7, 1999

In Brief: Wieand Named Director, Biostatistical Center For NSABP; LeMaistre Honored By AMA

June 30, 1995

NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit

April 29, 2005

Audit Finds NIH Conflict of Interest Reports Scattered, Inaccessible, And Incomplete.

January 25, 2008

Two founding cancer center directors step down: Harold Moses at Vanderbilt-Ingram and Charles Coltman at CTRC.

November 19, 2004